The abortion pill mifepristone "is not safe and effective," argue the authors of a new study that uses insurance claim data to examine adverse reactions to the pill. They claim to have found a "serious adverse event" rate of 10.93 percent, and they say this finding justifies renewed restrictions on mifepristone.
Sen. Josh Hawley (R–Mo.) seems to agree. The day the Ethics & Public Policy Center (EPPC) released its new mifepristone study, Hawley wrote to Food and Drug Administration (FDA) chief Marty Makary, urging the commissioner to "follow this new data and take all appropriate action to restore critical safeguards on the use of mifepristone."
Makary said in late April that he has "no plans" to restrict access to abortion pills. But he added that "there is an ongoing set of data that is coming into FDA on mifepristone. So if the data suggests something, or tells us that there's a real signal, we can't promise we're not going to act on that data that we have not yet seen."
